ISPE is pleased to announce that the Academie Nationale de Pharmacie has invited ISPE’s VP of European Operations Thomas Zimmer, PhD, to become a “Membre Correspondant Etranger” (Foreign Member). The Academy limits members from outside of France to 30 Membre Correspondant Etrangers, so it is indeed an honor for Thomas to be recognized with this exclusive invitation. Thomas, who lives in Germany, has been with ISPE since 2005.
Originally the Society of Pharmacy of Paris, the Academie Nationale de Pharmacie was founded in 1803. Recognized as a public utility in 1877, it became the Academie in 1946 and was named the Academie Nationale de Pharmacie in 1979. The Academie focuses on all areas of medicine, including public health, pharmacy, and health security, among other areas. Frequently consulted by different international ministries and various Agencies, the Academie develops reports and issues opinions or recommendations intended for public authorities, health professionals, and the general public. It approaches its topics with a multidisciplinary, rigorous, and scientific approach. Up to 20% of its members are non-pharmacists; this small percentage is made up of doctors, scientists, lawyers, and others.
“This is a great honor for me,” said Thomas. “I will have my inauguration in Paris in April/May with a scientific presentation in the local language. I’m very excited.” John Bournas, ISPE’s CEO and President, agrees. “We are proud of Thomas and look forward to hearing more about the stimulating work he will be undertaking as a Foreign Member of the Academie Francaise des Pharmaciens,” he said.
On behalf of all of ISPE, a hearty congratulations on this momentous achievement.
Through the ISPE Foundation Professional Development Grant program, Silas Tamufor attended the 2023 ISPE Annual Meeting & Expo in October 2023. Tamufor is a PhD student and ISPE Boston Chapter member who began serving as the ISPE Boston Educational Programs Committee Chair in December 2023. He, along with 87 other students and recent graduates, attended the conference thanks to the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...